Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

201-25: Keynote: Deep Dive into Medications for Schizophrenia, including Clozapine

Examine trends and emerging treatments to provide effective care to this population, including management of side effects.

Presenter:  Jonathan M. Meyer, MD, DLFAPA

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated.   Off-label uses will not be discussed during this presentation.

Jonathan M. Meyer, MD, DLFAPA is a speaker for Intra-Cellular Therapies Inc., AbbVie Pharmaceuticals, Alkermes, Axsome Therapeutics, Neurocrine Biosciences, Vanda Pharmaceuticals, Bristol Myers Squibb, 4M Therapeutics Inc., and Teva Pharmaceuticals. Dr. Meyer is a consultant for Alkermes, Axsome Therapeutics, AbbVie Pharmaceuticals, Bristol Myers Squibb, Intra-Cellular Therapies Inc., Neurocrine Biosciences, and Teva Pharmaceuticals.

Session Length:  2 hours

Target Audience:  APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Identify at least two antipsychotic medications used in the treatment of schizophrenia, including their mechanisms of action.

Keywords:  Schizophrenia, Antipsychotics, Emerging Treatments, Clozapine

Nursing Continuing Professional Development:
2.0 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and pass the post-test with a score of 80% or higher before the expiration date. Unlimited post-test attempts are allowed. Once all steps are successfully completed, the certificate will be generated online, available for you to print immediately. All steps must be successfully completed to earn contact hours. 

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 16, 2025
Access to this course will end: July 31, 2027

© 2025 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.